Autonomix Medical, Inc.

Autonomix Medical, Inc. released its latest CEO Corner segment, featuring CEO Brad Hauser, who highlighted the company's growing scientific and clinical recognition. The company has secured 13 abstract acceptances, including 9 podium and 4 poster presentations at major medical conferences, and received a top Cardiovascular Innovation Award at CRT. The segment also outlined how Autonomix's nerve-sensing and targeted therapy approach could transform treatments for complex conditions like pancreatic cancer pain, supporting future clinical trials and partnerships.

Autonomix Medical, Inc. announced its participation in a Virtual Investor "What This Means" segment, featuring Dr. Toufic Kachaamy, Chief of Medicine at City of Hope. Dr. Kachaamy discussed the clinical significance of data presented at the Society of Surgical Oncology Annual Meeting, focusing on the company's approach to managing visceral cancer pain and its differentiation from existing treatments. The discussion also covered the broader applicability of the findings beyond pancreatic cancer and how the results support the ongoing clinical development and feasibility of Autonomix's technology platform.

Autonomix Medical, Inc. has reported a correction of an error in previously issued financial statements within its 10-K filing. The development-stage medical device company also announced a pause in enrollment for its PoC 2 clinical expansion study for pancreatic cancer pain due to observed variability in early clinical outcomes. A revised clinical protocol, focusing on severe pancreatic cancer pain, was approved in April 2026, with U.S.-based clinical trials anticipated to commence in late 2026, subject to financing. The company, which has no product sales revenue, aims for regulatory clearance around 2028.

Autonomix Medical, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,544,131. This new patent, titled "Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall," significantly strengthens the company's global intellectual property portfolio. The patent covers catheter-based transvascular tools that enable real-time nerve activity sensing through vessel walls and objective assessment of treatment effectiveness, supporting a closed-loop, data-driven approach to nerve-targeted procedures.

Autonomix Medical, Inc. announced that two abstracts showcasing its innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, a leading interventional cardiovascular medicine course. The abstracts, focusing on pain mitigation in pancreatic cancer and precision-guided nerve illumination, highlight increasing clinical and scientific interest in the company's approach. Management emphasized that participation in such premier international forums is crucial for advancing awareness of their platform technology and its broad applicability across various disease states.

Autonomix Medical, Inc. announced that its long-term data, titled "Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation," has been accepted for presentation at Digestive Disease Week 2026 (DDW 2026), taking place from May 2–5, 2026. The data highlights long-term outcomes associated with the company's transvascular radiofrequency (RF) energy-based ablation approach, which aims to disrupt nerve signaling pathways responsible for severe pain in pancreatic cancer patients. This acceptance at a preeminent conference validates Autonomix's strategy and findings.

Autonomix Medical, Inc. announced it will present new long-term clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma at the European Conference on Interventional Oncology (ECIO) 2026. The presentation, scheduled for April 29, 2026, will highlight long-term outcomes from the company's ongoing clinical evaluation of its minimally invasive, transvascular RF energy-based approach. This addresses a significant unmet medical need for severe, difficult-to-manage pain associated with pancreatic cancer.